119 related articles for article (PubMed ID: 36990169)
1. Sequential-delivery nanocomplex for combined anti-angiogenesis and gene therapy against colorectal cancer.
Jia F; Li Y; Gao Y; Wang X; Lu J; Cui X; Pan Z; Xu C; Deng X; Wu Y
Int J Pharm; 2023 Apr; 637():122850. PubMed ID: 36990169
[TBL] [Abstract][Full Text] [Related]
2. Self-assembled fluorescent hybrid nanoparticles-mediated collaborative lncRNA CCAT1 silencing and curcumin delivery for synchronous colorectal cancer theranostics.
Jia F; Li Y; Deng X; Wang X; Cui X; Lu J; Pan Z; Wu Y
J Nanobiotechnology; 2021 Aug; 19(1):238. PubMed ID: 34380471
[TBL] [Abstract][Full Text] [Related]
3. Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer.
Zhao Z; Li Y; Shukla R; Liu H; Jain A; Barve A; Cheng K
Theranostics; 2019; 9(15):4508-4524. PubMed ID: 31285776
[TBL] [Abstract][Full Text] [Related]
4. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes.
Jin M; Jin G; Kang L; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2018; 13():2405-2426. PubMed ID: 29719390
[TBL] [Abstract][Full Text] [Related]
5. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
6.
Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
[TBL] [Abstract][Full Text] [Related]
8. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.
Lu ZX; Liu LT; Qi XR
Int J Nanomedicine; 2011; 6():1661-73. PubMed ID: 21904456
[TBL] [Abstract][Full Text] [Related]
9. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
10. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
11. Small interfering RNA for cancer treatment: overcoming hurdles in delivery.
Charbe NB; Amnerkar ND; Ramesh B; Tambuwala MM; Bakshi HA; Aljabali AAA; Khadse SC; Satheeshkumar R; Satija S; Metha M; Chellappan DK; Shrivastava G; Gupta G; Negi P; Dua K; Zacconi FC
Acta Pharm Sin B; 2020 Nov; 10(11):2075-2109. PubMed ID: 33304780
[TBL] [Abstract][Full Text] [Related]
12. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
[TBL] [Abstract][Full Text] [Related]
13. Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer.
Luo K; Gao Y; Yin S; Yao Y; Yu H; Wang G; Li J
Acta Biomater; 2021 Oct; 134():649-663. PubMed ID: 34289420
[TBL] [Abstract][Full Text] [Related]
14. Functionalized heparin-protamine based self-assembled nanocomplex for efficient anti-angiogenic therapy.
Alam F; Al-Hilal TA; Chung SW; Park J; Mahmud F; Seo D; Kim HS; Lee DS; Byun Y
J Control Release; 2015 Jan; 197():180-9. PubMed ID: 25445701
[TBL] [Abstract][Full Text] [Related]
15. Combining Fruquintinib and Doxorubicin in Size-Converted Nano-Drug Carriers for Tumor Therapy.
Zhang N; Xin X; Feng N; Wu D; Zhang J; Yu T; Jiang Q; Gao M; Yang H; Zhao S; Tian Q; Zhang Z
ACS Biomater Sci Eng; 2022 May; 8(5):1907-1920. PubMed ID: 35482571
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication.
Hoshino Y; Hayashida T; Hirata A; Takahashi H; Chiba N; Ohmura M; Wakui M; Jinno H; Hasegawa H; Maheswaran S; Suematsu M; Kitagawa Y
Mol Cancer; 2014 May; 13():102. PubMed ID: 24885802
[TBL] [Abstract][Full Text] [Related]
17. Localized controlled release of bevacizumab and doxorubicin by thermo-sensitive hydrogel for normalization of tumor vasculature and to enhance the efficacy of chemotherapy.
Darge HF; Andrgie AT; Hanurry EY; Birhan YS; Mekonnen TW; Chou HY; Hsu WH; Lai JY; Lin SY; Tsai HC
Int J Pharm; 2019 Dec; 572():118799. PubMed ID: 31678386
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
[TBL] [Abstract][Full Text] [Related]
19. A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy.
Lee SY; Yang CY; Peng CL; Wei MF; Chen KC; Yao CJ; Shieh MJ
Biomaterials; 2016 Apr; 86():92-105. PubMed ID: 26896610
[TBL] [Abstract][Full Text] [Related]
20.
Chen C; Zhang S; Zhang R; Sun P; Shi C; Abdalla M; Li A; Xu J; Du W; Zhang J; Liu Y; Tang C; Yang Z; Jiang X
Theranostics; 2020; 10(26):11998-12010. PubMed ID: 33204325
[No Abstract] [Full Text] [Related]
[Next] [New Search]
